Akari therapeutics plc - adr AKTX.US 總覽分析

美股醫療保健
(AKTX 無簡報檔)

AKTX 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

AKTX 近期報酬表現

11.90%

Akari therapeutics plc - adr

4.57%

同產業平均

3.26%

S&P500

與 AKTX 同產業的標的表現

  • IBO Impact biomedical inc
    價值 -趨勢 2 分波段 4 分籌碼 -股利 1 分
    查看更多

AKTX 公司資訊

Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.

AKTX 股價